%D8%A5%D9%86%D8%AF%D8%A7%D9%83%D8%A7%D8%AA%D9%8A%D8%B1%D9%88%D9%84Category:IndacaterolIndacaterolIndacaterolIndacat%C3%A9rolIndakaterolIndacaterolo%E3%82%A4%E3%83%B3%E3%83%80%E3%82%AB%E3%83%86%E3%83%AD%E3%83%BC%E3%83%ABIndakaterolIndakaterolIndakaterol%D0%86%D0%BD%D0%B4%D0%B0%D0%BA%D0%B0%D1%82%D0%B5%D1%80%D0%BE%D0%BBIndacaterolQ425654
about
P3781
A year in review: new drugs for older adults in 2011From libraries to candidate: the discovery of new ultra long-acting dibasic β₂-adrenoceptor agonists.Effect of long-acting beta-agonists on the frequency of COPD exacerbations: a meta-analysis.Efficacy of once-daily indacaterol 75 μg relative to alternative bronchodilators in COPD: a study level and a patient level network meta-analysisComparative efficacy of indacaterol in chronic obstructive pulmonary disease.Therapeutic potential for novel ultra long-acting β2-agonists in the management of COPD: biological and pharmacological aspects.Indacaterol: a review of its use as maintenance therapy in patients with chronic obstructive pulmonary disease.Comparison of indacaterol with tiotropium or twice-daily long-acting β -agonists for stable COPD: a systematic review.Indacaterol: a new long-acting β2-agonist in the management of chronic obstructive pulmonary disease.Indacaterol: a novel long-acting β(2) -agonist.Limitations of model based dose selection for indacaterol in patients with chronic obstructive pulmonary disease.Pharmacology and therapeutics of bronchodilators.Efficacy of indacaterol 75 μg versus fixed-dose combinations of formoterol-budesonide or salmeterol-fluticasone for COPD: a network meta-analysis.Combination of roflumilast with a beta-2 adrenergic receptor agonist inhibits proinflammatory and profibrotic mediator release from human lung fibroblasts.Slow receptor dissociation is not a key factor in the duration of action of inhaled long-acting β2-adrenoceptor agonistsClinical trial design in chronic obstructive pulmonary disease: current perspectives and considerations with regard to blinding of tiotropium.An investigation into the structure-activity relationships associated with the systematic modification of the β(2)-adrenoceptor agonist indacaterol.Metabolism and pharmacokinetics of indacaterol in humans.Efficacy of once-daily indacaterol relative to alternative bronchodilators in COPD: a patient-level mixed treatment comparison.Systemic pharmacokinetics of indacaterol, an inhaled once-daily long-acting beta2-agonist, in different ethnic populations.Acute effects of indacaterol on lung hyperinflation in moderate COPD: a comparison with tiotropiumEfficacy and safety of indacaterol 150 and 300 µg in chronic obstructive pulmonary disease patients from six Asian areas including Japan: a 12-week, placebo-controlled studyValidation of an on-line solid-phase extraction method coupled to liquid chromatography-tandem mass spectrometry detection for the determination of Indacaterol in human serumConcurrent use of indacaterol plus tiotropium in patients with COPD provides superior bronchodilation compared with tiotropium alone: a randomised, double-blind comparison▾Indacaterol for COPD
P921
description
Arzneistoff
@de
chemesch Verbindung
@lb
chemical compound
@en
chemical compound
@en-ca
chemical compound
@en-gb
chemická sloučenina
@cs
chemická zlúčenina
@sk
chemiese verbinding
@af
chemische Verbindung
@de-ch
chemische verbinding
@nl
name
Indacaterol
@de
Indacaterol
@nl
Indacaterol
@vi
Indakaterol
@hu
Indakaterol
@sh
Indakaterol
@sr
indacaterol
@en
indacaterolo
@it
indacaterolum
@la
indacatérol
@fr
type
label
Indacaterol
@de
Indacaterol
@nl
Indacaterol
@vi
Indakaterol
@hu
Indakaterol
@sh
Indakaterol
@sr
indacaterol
@en
indacaterolo
@it
indacaterolum
@la
indacatérol
@fr
altLabel
5-[2-(5,6-diethylindan-2-ylamino)-1-hydroxyethyl]-8-hydroxy-1H-quinolin-2-one
@en
QAB 149
@en
QAB-149
@en
QAB149
@en
prefLabel
Indacaterol
@de
Indacaterol
@nl
Indacaterol
@vi
Indakaterol
@hu
Indakaterol
@sh
Indakaterol
@sr
indacaterol
@en
indacaterolo
@it
indacaterolum
@la
indacatérol
@fr